文献速递治疗药物监测与药物基因组学特殊人群用药

肾移植受者他克莫司剂量算法避免暴露不足与过度的前瞻性干预试验

Avoiding Tacrolimus Underexposure and Overexposure with a Dosing Algorithm for Renal Transplant Recipients: A Single Arm Prospective Intervention Trial.
PubMed 文献 · Clin Pharmacol Ther · 2021-02-23

该单臂前瞻性治疗干预试验纳入60例初治肾移植受者,采用基于CYP3A4/CYP3A5基因型、体表面积和年龄的剂量算法确定他克莫司起始剂量。移植后第3天58%(90%CI 47-68%)的患者他克莫司C0处于目标范围7.5-12.5 ng/mL,明显低于治疗浓度和高于治疗浓度者分别占7%和3%,活检证实的急性排斥反应发生3例(5%)。

要点

  • 基于CYP3A4/CYP3A5基因型、体表面积和年龄的算法可指导他克莫司起始剂量。
  • 移植后第3天58%患者他克莫司C0达目标范围7.5-12.5 ng/mL。
  • 明显低于治疗浓度(<5.0 ng/mL)和高于治疗浓度(>20 ng/mL)分别占7%和3%。

核心结论

  • 基于算法的他克莫司给药可使58%的肾移植受者在移植后第3天达到目标C0。

研究设计与样本

  • 单臂前瞻性治疗干预试验,纳入60例初治肾移植受者,排除1例方案违背后分析59例。

主要发现

  • 移植后第3天,34/59例(58%,90%CI 47-68%)他克莫司C0处于7.5-12.5 ng/mL目标范围。
  • 明显低于治疗浓度(<5.0 ng/mL)者占7%,高于治疗浓度(>20 ng/mL)者占3%。
  • 活检证实的急性排斥反应发生于3例患者(5%)。

关键数值与推荐

  • 目标他克莫司C0为7.5-12.5 ng/mL,于移植后第3天首次测量。
  • 算法包含CYP3A4和CYP3A5基因型、体表面积和年龄作为协变量。

临床怎么用

  • 肾移植受者可考虑采用包含CYP3A4/CYP3A5基因型、体表面积和年龄的算法确定他克莫司起始剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bodyweight-based tacrolimus dosing followed by therapeutic drug monitoring is standard clinical care after renal transplantation. However, after transplantation, a meager 38% of patients are on target at first steady-state and it can take up to 3 weeks to reach the target tacrolimus predose concentration (C0 ). Tacrolimus underexposure and overexposure is associated with an increased risk of rejection and drug-related toxicity, respectively. To minimize subtherapeutic and supratherapeutic tacrolimus exposure in the immediate post-transplant phase, a previously developed dosing algorithm to predict an individual's tacrolimus starting dose was tested prospectively. In this single-arm, prospective, therapeutic intervention trial, 60 de novo kidney transplant recipients received a tacrolimus starting dose based on a dosing algorithm instead of a standard, bodyweight-based dose. The algorithm included cytochrome P450 (CYP)3A4 and CYP3A5 genotype, body surface area, and age as covariates. The target tacrolimus C0 , measured for the first time at day 3, was 7.5-12.5 ng/mL. Between February 23, 2019, and July 7, 2020, 60 patients were included. One patient was excluded because of a protocol violation. On day 3 post-transplantation, 34 of 59 patients (58%, 90% CI 47-68%) had a tacrolimus C0 within the therapeutic range. Markedly subtherapeutic (< 5.0 ng/mL) and supratherapeutic (> 20 ng/mL) tacrolimus concentrations were observed in 7% and 3% of the patients, respectively. Biopsy-proven acute rejection occurred in three patients (5%). In conclusion, algorithm-based tacrolimus dosing leads to the achievement of the tacrolimus target C0 in as many as 58% of the patients on day 3 after kidney transplantation.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Francke MI, Andrews LM, Le HL, et al. Avoiding Tacrolimus Underexposure and Overexposure with a Dosing Algorithm for Renal Transplant Recipients: A Single Arm Prospective Intervention Trial. Clin Pharmacol Ther. 2021. PMID: 33452682. doi:10.1002/cpt.2163

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。